SS Innovations International Performs World's First Robotic Cardiac Telesurgeries with its SSi Mantra 3
SS Innovations International (OTC: SSII) has achieved a historic milestone in global healthcare by successfully performing the world's first robotic cardiac telesurgeries using its SSi Mantra 3 Surgical Robotic System. The procedures, including a robotic-assisted Internal Mammary Artery Harvesting and a Robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB), were conducted remotely between Gurugram and Jaipur, India, spanning 286 kilometers with a latency of only 40 milliseconds.
This breakthrough was made possible due to the recent approval from the Central Drugs Standard Control Organization (CDSCO), India's regulatory authority, making SS Innovations the first in India to receive such approval for telesurgery and teleproctoring capabilities. The SSi Mantra 3 system has been clinically validated in over 80 different types of surgical procedures in India and is awaiting FDA and CE Mark approvals by the second half of 2025.
The success of these telesurgeries underscores the potential of advanced surgical technology in overcoming geographical barriers, enabling timely and precise medical care. It also marks a significant step forward in making high-quality healthcare accessible to underserved communities, particularly in rural areas.
SS Innovations International (OTC: SSII) ha raggiunto una pietra miliare storica nella sanità globale eseguendo con successo le prime telesurgery cardiache robotiche al mondo utilizzando il proprio SSi Mantra 3 Surgical Robotic System. Le procedure, tra cui un prelievo della arteria mammaria interna assistito da robot e un bypass coronarico totalmente endoscopico su cuore battente (TECAB), sono state condotte a distanza tra Gurugram e Jaipur, in India, su una distanza di 286 chilometri con una latenza di soli 40 millisecondi.
Questo progresso è stato reso possibile grazie all'approvazione recente da parte del Central Drugs Standard Control Organization (CDSCO), l'autorità di regolamentazione indiana, che ha reso SS Innovations la prima in India a ricevere tale approvazione per le capacità di telesurgery e teleproctoring. Il sistema SSi Mantra 3 è stato convalidato clinicamente in oltre 80 diversi tipi di procedure chirurgiche in India e attende le approvazioni della FDA e del marchio CE entro la seconda metà del 2025.
Il successo di queste telesurgery sottolinea il potenziale delle tecnologie chirurgiche avanzate nel superare le barriere geografiche, permettendo cure mediche tempestive e precise. Rappresenta anche un significativo passo avanti per rendere accessibile un'assistenza sanitaria di alta qualità alle comunità svantaggiate, in particolare nelle aree rurali.
SS Innovations International (OTC: SSII) ha alcanzado un hito histórico en la atención sanitaria global al realizar con éxito las primeras telesurgery cardíacas robóticas del mundo utilizando su SSi Mantra 3 Surgical Robotic System. Los procedimientos, que incluyen la recolección de la arteria mamaria interna asistida por robot y un bypass coronario totalmente endoscópico sobre un corazón latiendo (TECAB), se llevaron a cabo de forma remota entre Gurugram y Jaipur, India, abarcando 286 kilómetros con una latencia de solo 40 milisegundos.
Este avance fue posible gracias a la reciente aprobación de la Central Drugs Standard Control Organization (CDSCO), la autoridad reguladora de India, lo que convierte a SS Innovations en la primera en recibir tal aprobación para las capacidades de telesurgery y teleproctoring en India. El sistema SSi Mantra 3 ha sido validado clínicamente en más de 80 tipos diferentes de procedimientos quirúrgicos en India y está a la espera de las aprobaciones de la FDA y del marcado CE para la segunda mitad de 2025.
El éxito de estas telesurgery subraya el potencial de la tecnología quirúrgica avanzada para superar las barreras geográficas, permitiendo atención médica oportuna y precisa. También marca un paso significativo hacia la accesibilidad de atención médica de alta calidad para comunidades desatendidas, especialmente en áreas rurales.
SS Innovations International (OTC: SSII)는 SSi Mantra 3 Surgical Robotic System을 사용하여 세계 최초로 로봇 심장 원격 수술을 성공적으로 수행함으로써 글로벌 헬스케어에서 역사적인 이정표를 세웠습니다. 내장된 로봇 지원 흉부 내장동맥 채취 및 로봇 비트 심장 완전 내시경 관상 동맥 우회 수술(TECAB) 등 다양한 수술이 인도 구르가온과 자이푸르 간에 286킬로미터 떨어진 거리에서 단 40밀리초의 지연으로 원격으로 이루어졌습니다.
이번 혁신은 인도의 규제 기관인 Central Drugs Standard Control Organization (CDSCO)의 최근 승인을 통해 가능해졌으며, SS Innovations가 인도에서 원격 수술 및 원격 연수지원 기능에 대한 승인을 최초로 받았습니다. SSi Mantra 3 시스템은 인도에서 80가지 이상의 다양한 수술 절차에 대해 임상적으로 검증되었으며, 2025년 하반기에는 FDA 및 CE 마크 승인을 기다리고 있습니다.
이번 원격 수술의 성공은 첨단 수술 기술이 지리적 장벽을 극복하고 적시의 정확한 의료 서비스를 제공하는 잠재력을 강조합니다. 또한, 특히 농촌 지역에서 소외된 커뮤니티가 양질의 의료 서비스를 이용할 수 있는 중요한 진전을 나타냅니다.
SS Innovations International (OTC: SSII) a atteint un jalon historique dans le domaine de la santé mondiale en réalisant avec succès les premières télésurgeries cardiaques robotiques au monde en utilisant son SSi Mantra 3 Surgical Robotic System. Les procédures, y compris la collecte de l'artère mammaire interne assistée par robot et un pontage coronarien endoscopique total sur cœur battant (TECAB), ont été effectuées à distance entre Gurugram et Jaipur, en Inde, sur une distance de 286 kilomètres avec une latence de seulement 40 millisecondes.
Cette avancée a été rendue possible grâce à l'approbation récente de l'Central Drugs Standard Control Organization (CDSCO), l'autorité de régulation en Inde, faisant de SS Innovations le premier en Inde à recevoir une telle approbation pour les capacités de télésurgery et de téléproctoring. Le système SSi Mantra 3 a été validé cliniquement dans plus de 80 types différents de procédures chirurgicales en Inde et attend des approbations de la FDA et du marquage CE d'ici la seconde moitié de 2025.
Le succès de ces télésurgeries souligne le potentiel des technologies chirurgicales avancées à surmonter les barrières géographiques, permettant des soins médicaux rapides et précis. Cela représente également une avancée significative vers l'accès à des soins de santé de haute qualité pour les communautés défavorisées, en particulier dans les zones rurales.
SS Innovations International (OTC: SSII) hat einen historischen Meilenstein im globalen Gesundheitswesen erreicht, indem es erfolgreich die weltweit ersten robotergestützten kardialen Telesurgiken mit dem SSi Mantra 3 Surgical Robotic System durchgeführt hat. Die Verfahren, einschließlich der robotergestützten Ernte der inneren Brustarterie und einem roboterunterstützten vollständigen endoskopischen koronaren Bypass (TECAB), wurden remote zwischen Gurugram und Jaipur in Indien durchgeführt und erstreckten sich über 286 Kilometer mit nur 40 Millisekunden Latenz.
Dieser Durchbruch wurde durch die kürzliche Genehmigung des Central Drugs Standard Control Organization (CDSCO), der indischen Aufsichtsbehörde, möglich, wodurch SS Innovations das erste Unternehmen in Indien ist, das eine solche Genehmigung für Telesurgery und Teleproctoring erhalten hat. Das SSi Mantra 3 System wurde in über 80 verschiedenen Arten von chirurgischen Eingriffen in Indien klinisch validiert und wartet bis zur zweiten Hälfte 2025 auf die Genehmigungen durch die FDA und das CE-Zeichen.
Der Erfolg dieser Telesurgiken unterstreicht das Potenzial fortschrittlicher chirurgischer Technologien, geografische Barrieren zu überwinden und rechtzeitige sowie präzise medizinische Versorgung zu ermöglichen. Er stellt auch einen bedeutenden Schritt zur Verbesserung des Zugangs zu hochwertiger Gesundheitsversorgung für benachteiligte Gemeinschaften dar, insbesondere in ländlichen Gebieten.
- Successful completion of world's first robotic cardiac telesurgeries.
- Low latency of only 40 milliseconds for remote procedures.
- Received CDSCO approval for telesurgery and teleproctoring capabilities.
- Clinically validated in over 80 different types of surgical procedures in India.
- Potential for FDA and CE Mark approvals by the second half of 2025.
- None.
- A Robotic-Assisted Internal Mammary Artery Harvesting Telesurgery procedure was successfully completed in 58 minutes.
- The world’s first Robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) Telesurgery was performed with a latency of only 40 milliseconds (less than 1/20th of a second).
- The procedures were performed using the SSi Mantra 3 Surgical Robotic System which was remotely connected from SS Innovations’ headquarters in Gurugram, India to Manipal Hospital in Jaipur, Rajasthan, a distance of 286 kilometers.
- SS Innovations is the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO) regulatory approval for Telesurgery and Teleproctoring capabilities of a surgical robotic system. The CDSCO is India’s equivalent to the United States Food and Drug Administration (FDA).
FORT LAUDERDALE, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable for and accessible to a global population, has made history in global healthcare by successfully performing two world-first robotic cardiac telesurgeries in just two days, a feat that has never been accomplished before. This achievement, made possible by the SSi Mantra 3 Surgical Robotic System, involved remotely connecting SS Innovations' headquarters in Gurugram, India with Manipal Hospital in Jaipur, Rajasthan, spanning a distance of 286 kilometers. This milestone opens the door to a future where advanced surgical technology becomes a key component of accessible and efficient global healthcare.
The first telesurgery procedure, a remotely conducted robotic-assisted Internal Mammary Artery Harvesting procedure was successfully completed in just 58 minutes. The surgical team was led by Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations, from the Company’s Headquarters in Gurugram, and supported by Dr. Lalit Malik, Chief of Cardiac Surgery at Manipal Hospital, Jaipur, along with his expert team at the remote location in Jaipur. The telesurgery demonstrated precision with a low latency of just 35-40 milliseconds (less than 1/20th of a second). This groundbreaking procedure was followed by another world-first, a Robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB), a procedure known as one of the most complex Cardiac Surgical procedures; performed via telesurgery under the same collaboration, also with a low latency of just 40 milliseconds.
Both telesurgeries, conducted by remote connection from Gurugram to Jaipur, showcased seamless teamwork across long distances, setting a new standard for remote surgical interventions. These achievements underscore the transformative potential of telesurgery in overcoming geographical barriers, enabling timely, high-quality medical care with a high degree of accuracy.
The SSi Mantra 3 Surgical Robotic System is the only robotic system in the world to have received regulatory approval for telesurgery and tele-proctoring. Approved by the Central Drugs Standard Control Organization (CDSCO), this validation opens the door to remote surgeries and medical education, enabling healthcare professionals to collaborate across distances. It highlights the transformative potential of technology in enhancing the accessibility and precision of healthcare, revolutionizing how surgeries are performed on a global scale. By bringing world-class medical expertise to even the most remote corners of the globe, it sets a groundbreaking precedent for the future of remote healthcare, reshaping patient care.
Expressing immense gratitude for this historic feat, SS Innovations’ Founder, Chairman, and CEO, Dr. Sudhir Srivastava, said, “We are extremely thrilled to have advanced the capabilities of surgery to benefit humanity, especially in areas that need it the most. By enabling telesurgery, we can bridge gaps in access to medical expertise and deliver the highest standard of care, regardless of geographical barriers. For a country like India, with its vast rural population and significant healthcare disparities, this innovation has the potential to be transformative. Telesurgery brings world-class surgical expertise directly to underserved communities, eliminating the need for patients to travel long distances to urban centers for specialized care. It ensures timely interventions while reducing logistical and financial burdens on families. With the recent CDSCO approval for telesurgery using SSi Mantra, we have not just advanced technology; we have fulfilled our mission to democratize access to robotic surgery. Our goal has always been to make advanced surgical care affordable and accessible, and telesurgery now allows us to extend the reach of skilled surgeons to every corner of our nation, fundamentally changing the way healthcare is delivered.”
Dr. Lalit Malik, Chief of Cardiac Surgery at Manipal Hospital, Jaipur, said, “We believe that this groundbreaking inter-state robotic cardiac telesurgery marks a significant advance in enhancing patient care through innovation. The remote robotic-assisted CABG on an elderly patient from Jaipur demonstrates how technology can bridge geographical gaps to provide accurate and timely medical interventions. This achievement underscores our dedication to offering world-class healthcare and ensuring patients have access to the most advanced treatment options available.”
Commenting on this milestone, Dr. Fredric Moll, Father of Surgical Robotics, and Founder of Intuitive Surgical and SS Innovations’ Vice-Chairman, said, “I would like to extend my heartfelt congratulations to Dr. Srivastava and the entire team on the successful achievement of performing the world’s first robotic cardiac telesurgeries. It is wonderful to see just how far we have come since the inception of surgical robotics more than 20 years ago. As many may recall, the original robotic system was designed to achieve two things, remote surgery and the ability to perform coronary bypass surgery in a complete closed chest approach. My approach had been that, if you could perform beating heart bypass surgery with the robot, then all other procedures would be possible. Due to the bandwidth limitations at the time, the telesurgery goal was put on hold while we further broadened the applications of the surgical robotic system across all specialties. I believe that SS Innovations has seized the opportunity, to not only develop the next generation of a surgical robotic system, but to also push the envelope of just what was dreamed of more than 20 years ago, achieving a successful demonstration of telesurgery coupled along with a highly complex cardiac surgical procedure. With this achievement, I have no doubt that certainly more opportunities will present themselves as we have now entered into a new paradigm shift towards surgery and how we will soon approach it.”
This historic achievement marks a significant step forward in India’s healthcare landscape, with the Company leading the charge in revolutionizing surgical care through both cutting-edge technology coupled with a humanitarian vision. The approval of Telesurgery and Tele proctoring capabilities for the SSi Mantra Surgical Robotic System not only underscores the company’s commitment to innovation but also opens up new possibilities for accessible, high-quality healthcare across India and beyond. As SS Innovations continues to expand the boundaries of medical technology, it remains dedicated to transforming healthcare delivery, making advanced treatments more accessible, and ultimately improving the lives of patients worldwide.
About SS Innovations:
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SS Innovations’ business operations are headquartered in India and the Company plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit our website at ssinnovations.com or LinkedIn for updates.
About the SSi Mantra:
The SSi Mantra Surgical Robotic System, by SS Innovations, is a modular multi-arm system with many advanced technology features. It allows for the use of 3-5 robotic arms, has an open-faced ergonomic Surgeon Command Centre, 32-inch large 3D 4K monitor, a 23-inch 2D Touch panel monitor for all patient related information display, a virtual real-time image of the robotic Patient Side Arm Carts, and the ability for superimposition of 3D models of diagnostic imaging. The Vision Cart gives the table-side team the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The modular robotic arms give flexibility in positioning and the number of arms to be used. This allows for collision-free conduct of surgical operations. There are over 40 different types of robotic endo-surgical instruments that can be used for different specialties including cardiac surgery. The learning curve for surgeons is shorter due to the SSi Mantra’s ergonomic design and user-friendly features.
The SSi Mantra has been clinically validated in India in more than 80 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving FDA approval to market and CE Mark approval in the second half of 2025.
Follow us on:
LinkedIn: https://www.linkedin.com/company/ssinnovationsgroup/
YouTube: https://www.youtube.com/@ssinnovations
For media inquiries, please contact:
+1-212-739-0300
FAQ
What does the SSII buyback mean for shareholders?
How did SS Innovations achieve the world's first robotic cardiac telesurgeries?
What is the significance of the CDSCO approval for SS Innovations?
When can SS Innovations expect FDA and CE Mark approvals for the SSi Mantra 3?
How did the SSi Mantra 3 system perform in the recent telesurgeries?
What are the benefits of telesurgery for underserved communities?
